# BPC-157 TB-500 Dosage in the Research Literature | Routes, Half-Life, Handling > BPC-157 TB-500 dosage as it appears in the research record: per-body-weight animal doses for each constituent, no validated blend dose, and no human PK half-life for the combination. Animal-model dose ranges per constituent, the routes that appear in the literature, and the plain fact that no validated blend dose or human pharmacokinetic profile exists. ## BPC-157 TB-500 dosage in the research literature BPC-157 TB-500 dosage has no validated value for the BLEND. There is no peer-reviewed combination dose-finding study, so any "protocol" for the pair is extrapolated from single-compound animal work, not measured for the combination [9]. What the literature does contain is per-constituent, per-body-weight dosing in research models — described here strictly as what was administered to which species, never as human guidance. For the BPC-157 component, rodent studies commonly express dose per body weight, frequently around `10 microg/kg` and `10 ng/kg`; gastric-ulcer cytoprotection has been studied at `400-800 ng/kg` in rats [1]. For the TB-500 / Thymosin Beta-4 component, the range is wide: a rat embolic-stroke dose-response study used `2-18 mg/kg` intraperitoneally, modeled an optimum near `3.75 mg/kg`, and found `18 mg/kg` gave no benefit — direct evidence that higher is not better [9]. A muscular-dystrophy study dosed `150 microg` twice weekly intraperitoneally for six months [9]. Commercial "Wolverine" vials commonly pair the two at a fixed combined mass — for example ~10 mg BPC-157 plus ~10 mg TB-500 per vial — but that ratio has no controlled-trial basis [9]. These figures describe the research record; none is a dose for a person. ## What dosing frequency appears in the research literature? Dosing frequency in the underlying studies was set by experimental design, not by any human schedule. The rodent efficacy work for both peptides typically used per-body-weight doses by injection (often intraperitoneal), and a representative Thymosin Beta-4 study dosed twice weekly over months [9]. There is no validated dose or schedule for the blend. Community "loading then maintenance" protocols and fixed-ratio vials have no basis in controlled human trials [9]. The non-monotonic dose-response noted above — `18 mg/kg` worse than a lower modeled optimum in the stroke model — is exactly the kind of finding a simple loading rationale ignores [9]. ## What is the half-life of BPC-157 and TB-500? No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157's elimination half-life was reported at under 30 minutes in a rat/dog PK study [9]. Human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses [5][6], but no specific half-life is established for the TB-500 heptapeptide. That gap matters for the blend twice over: not only is there no combination PK, but the human PK that does exist belongs to the full-length protein, not the 7-mer that is actually sold as "TB-500" [5][6]. ## Routes studied for the BPC-157 TB-500 blend Several routes appear across the record. The predominant research-community routes for the blend — the "Wolverine injection" register — are subcutaneous and intramuscular, but those are community practices, not routes validated in controlled human efficacy trials [9]. The underlying rodent efficacy studies for both peptides predominantly used intraperitoneal dosing [1][9]. Human Phase 1 work on full-length Thymosin Beta-4 was intravenous [5][6], and individual-compound wound and tendon models have used local, intra-lesional, and topical routes [4]. None of this constitutes administration guidance. Route and dose in animal models do not translate to a person, and the blend itself has no validated route. ## Oral versus injectable in the research literature The "BPC 157 TB 500 oral" question turns on a real asymmetry between the two records. BPC-157 is studied as a "stable gastric" peptide and has been examined by peroral as well as parenteral routes in animal models [1]. The TB-500 fragment has no comparable validated oral pharmacokinetics. Blend oral products are marketed, but they lack validated PK, and the combination's oral absorption is uncharacterized [9]. So "oral" is plausible for one record and unestablished for the other and for the pair — another reason the blend's behavior cannot be read off either constituent alone. ## How is a BPC-157 / TB-500 blend reconstituted for research? Both constituents are supplied as lyophilized (freeze-dried) powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. A common laboratory practice is to reconstitute the two peptides separately or in a shared vial [9]. Two caveats attach to [reconstitution and handling](/dosage). First, product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed — which compounds the existing identity caveat that "TB-500" is the 7-mer while most efficacy data are for full-length Thymosin Beta-4 [4][9]. Second, this describes laboratory handling, not human-use guidance. It is included because reconstitution is a frequent practical question about the material, not as instruction for administration. --- Two peptides logged as two records on one console — BPC-157 and TB-500 each weighed against its own studies and its 503A status, the combination row left reading NO-HUMAN-DATA, with no clinic behind the panel and nothing here dispensed.